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Previewscells remains highly controversial, with
different studies postulating an important
function in HSCs, or no role whatsoever
(Cerdan and Bhatia, 2010; Maillard et al.,
2008). The role of wnt signaling in HSCs
is equally unclear, with claims of a role in
controlling hematopoietic stem and
progenitor fates, or that it is dispensable
in HSCs (Malhotra and Kincade, 2009;
Cerdan and Bhatia, 2010). It will be inter-
esting to see if these novel insights into
the role of wnt signaling in HSC specifica-
tion can also help to clarify potential roles
in the complex niches of adult HSCs.
Although the current study includes
some indications of the cellular source of
the wnt16, precise identification of the
specific wnt16-producing cell type, and
of the molecular control of its expression,
will be necessary to comprehensively
unravel blood specification. The simulta-
neous requirement of two independent
Notch ligands is puzzling and of wide
interest. Part of the mechanisms behind
this synergy has probably just been
described in another recent publication
(Wright et al., 2011). It will be important
to determine whether the molecular
mechanism described by Traver and4 Cell Stem Cell 9, July 8, 2011 ª2011 Elsevicolleagues also functions in mammalian
development. This study very nicely
confirms and illustrates the existence of
specific, sequential windows of time at
which defined combinatorial environ-
mental cues ultimately lead to HSC spec-
ification. A similar signaling requirement
that specifies cell fate choices—long after
the signals themselves were active—was
recently shown for BMP in the in vitro
generation of blood cells from ESCs
(Chiang and Wong, 2011). Molecular
programs that propagate over time by
either non-cell-autonomous relay signal-
ing or cell-intrinsic deterministic mecha-
nisms are not only highly interesting as
models for molecular regulation. In com-
bination with the required timed presence
of many different cell types and their
inductive signaling, they can also offer
an explanation for the remaining difficulty
in inducing HSCs from pluripotent cells
(Cerdan and Bhatia, 2010). Hopefully,
these novel insights will contribute to the
comprehensive understanding of the re-
quired combinatorial timed signals (Ciau-
Uitz et al., 2010) that will allow the efficient
generation of unlimited, well-defined, and
clinically applicable HSCs in vitro.er Inc.REFERENCES
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Myc/Max complexes are thought to be essential for maintaining pluripotency and self-renewal of embryonic
stem cells (ESCs). In this issue of Cell Stem Cell, Hishida et al. (2011) provide genetic evidence that this
requirement can be bypassed in well-defined culture conditions.Due to its pervasive involvement in human
tumorigenesis, the Myc oncoprotein and
two of its cousins, N-Myc and L-Myc,
have been under intense scrutiny for
many years. More recently, endogenous
c- and N-Myc proteins have been demon-
strated to be individually or collectively
essential for the self-renewal of embry-
onic and adult (e.g., hematopoietic) stem
cells (Smith and Dalton, 2010). Impor-tantly, deregulated expression of Myc,
as is the hallmark of many human tumors,
enhances the formation of induced plurip-
otent stem cells (iPSCs), suggesting that
the oncogenic functions of Myc may be
mechanistically related to its ability to
confer self-renewal capacity to differenti-
ated cells given the right genetic context
(Takahashi and Yamanaka, 2006). As a
result, the biochemical analysis of Mycfunction, particularly in ESCs, has begun
to set paradigms for the study of Myc in
human tumors.
Myc has an essential role in maintaining
ESCs in a proliferative, self-renewing, and
undifferentiated state. Together with a
set of interacting proteins, Myc binds to
a large set of promoters that are distinct
from promoters bound by other factors
involved in maintaining the pluripotency
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Figure 1. Myc/Max Complexes Can Be Dispensable for ESC Pluripotency
Both alleles of theMax gene are disrupted in the Max null ESCs, and a doxycycline-regulatableMax cDNA
is expressed from the ROSA26 locus. The lack of functional Myc/Max complexes induces the differenti-
ation and subsequent apoptosis of Max null ESCs, unless cells express Nanog or are cultured in the
presence of MAP kinase and GSK3 inhibitors.
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module’’ genes) (Kim et al., 2010). Expres-
sion of Myc module genes is downregu-
lated during differentiation, concomitant
with loss of Myc expression. Furthermore,
expression of genes of this module is
enhanced in human tumors, often corre-
lating with their aggressiveness, underlin-
ing the similarity between oncogenic and
stem cell functions of Myc (Ben-Porath
et al., 2008). The observation that Myc is
a global regulator of transcriptional
elongation and phosphorylation of RNA
polymerase II suggests a mechanistic
basis for gene activation by Myc in mouse
ESCs (mESCs) (Rahl et al., 2010). Taken
together, the data support a model in
which one key mechanism by which Myc
acts to maintain ESC pluripotency is by
enhancing the expression of a large set
of genes that in some way collectively
promote pluripotency.
The current manuscript in this issue of
Cell Stem Cell by Hishida et al. (2011)
tests some of the predictions of this
model by analyzing mESCs that in es-
sence have an inducible knockout of the
Max protein (Figure 1). Max is a partner
protein of Myc that is required for all
known functions of Myc proteins. The
sole exception is Myc’s function in pro-
moting transcription by RNA polymerase
III, which is mediated by a direct contact
of Myc with TFIIIB, so the ability to pro-
mote RNA polymerase III-dependent
transcription may be retained in Max-
less ESCs (Gallant and Steiger, 2009).
In line with previous results, Hishida
et al. find that loss of Max in mESCs leads
to loss of self-renewal, inhibition of cell
proliferation, differentiation, and, as an
indirect consequence, apoptosis (Fig-ure 1). Loss of the undifferentiated state
is accompanied by upregulation of MAP
kinase signaling, a known inducer of ESC
differentiation. How loss of Max induces
MAP kinase activity remains open. Also
in line with previous work, loss of Max
leads to a downregulation of genes of
the Myc module. Most genes of the mod-
ules are only weakly affected, although
the effects are stronger on a subset of
206 genes.
Surprisingly, however, loss of Max in
mESCs has no effect on the expression
of genes that were downregulated by the
concomitant deletion of c- and N-Myc in
hematopoietic stem cells, arguing that
there is virtually no overlap in Myc/Max-
regulated genes between both cell
types—although in both cases Myc/Max
complexes are required for maintaining
self-renewal capacity. Even more sur-
prisingly, expression of Nanog inhibits
differentiation and permits long-term pro-
liferation of Max-depleted mESCs (Fig-
ure 1). Nanog-rescued cells maintain
expression of Myc-module genes in the
absence of Max. So if Myc/Max com-
plexes have a direct and critical function
in upregulating Myc module genes, this
function cannot be unique and can be
quite easily substituted or bypassed by
expression of Nanog or one of its down-
stream target genes.
Furthermore, previous work had dem-
onstrated that mESCs can exist in a
‘‘ground state,’’ in which they self-renew
and maintain pluripotency, independent
of extrinsic stimuli such as leukemia inhib-
itory factor (LIF) and its intracellular target,
Stat3 (Ying et al., 2008). This ground state
can be induced by inhibiting MAP kinase
signaling and by inhibiting GSK3 (resultingCell Stemin the so called ‘‘2i’’ condition), thereby
blocking differentiation and promoting
the biosynthetic capacities of mESCs.
Myc levels are very low in ground state
mESCs, which prompted Hishida et al.
to test whether the 2i condition drives
self-renewal of mESCs without Myc/Max
transcriptional complexes. Indeed, they
found that Myc module genes show a
marginal decrease in expression (on
average a 10% decrease) when Max is
deleted under 2i culture conditions, rein-
forcing the notion that loss of Myc/
Max complexes can be largely dispens-
able for maintaining expression of Myc
module genes.
A final surprise is contained in one of
the Supplemental Figures. Based on the
use of a small molecule inhibitor, 10058-
F4, that disrupts heterodimerization of
Myc and Max in vitro and inhibits cell
proliferation, Young and colleagues con-
cluded in a recent publication that a
central function ofMyc is to promote elon-
gation by RNA polymerase II (Rahl et al.,
2010). One piece of evidence is the finding
that addition of high concentrations of
10058-F4 inhibits phosphorylation of
RNA polymerase II at serine 2, a hallmark
of elongating RNA polymerase. A predic-
tion from this model is that the genetic
ablation of Max should have the same
effect, yet Hishida et al. show that this
does not occur, arguing that the function
of Myc/Max complexes in transcriptional
elongation can be provided by the substi-
tution of other factors.
Collectively, the findings that Myc/Max
complexes can be dispensable for self-
renewal and maintaining expression of
Myc module genes (Figure 1) argue
against a model in which Myc/Max com-
plexes have an essential and mechanisti-
cally unique role in upregulating expres-
sion of a large group of downstream
target genes to promote self-renewal. An
alternative model suggesting that a
smaller set of specific target genes medi-
ates the effects of Myc on self-renewal is
supported by recent studies showing
that repression of the primitive endoderm
master regulator GATA6 and regulation of
miRNA expression contribute to Myc’s
ability to maintain pluripotency (Lin et al.,
2009; Smith and Dalton, 2010). These
findings are also reminiscent of ob-
servations in Drosophila, in which larval
development can be completed in the
absence of dMyc, provided its antagonist,Cell 9, July 8, 2011 ª2011 Elsevier Inc. 5
Cell Stem Cell
PreviewsdMnt/dMad, is also deleted (Pierce et al.,
2008). Analogously, it is possible that the
conditions that render Max dispensable
in mESCs affect the abundance and
function of Mad/Mnt proteins. If so, the
observations reported here suggest that
the relative abundance of Myc/Max and
Mad/Max complexes at a large number
of ESC promoters reflects the need to
alter expression of the bound genes—
and subsequently cell growth and prolif-
eration—in response to developmental
signals, rather than a direct role of these
genes as an integral part of establishing
and maintaining pluripotency.6 Cell Stem Cell 9, July 8, 2011 ª2011 ElseviREFERENCES
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